CHAPTER III . SECTION 3

AI Act Article 22: Authorised representatives of providers of high-risk AI systems

1. Prior to making their high-risk AI systems available on the Union market, providers established in third countries shall, by written mandate, appoint an authorised representative which is established in the Union.

2. The provider shall enable its authorised representative to perform the tasks specified in the mandate received from the provider.

3. The authorised representative shall perform the tasks specified in the mandate received from the provider. It shall provide a copy of the mandate to the market surveillance authorities upon request, in one of the official languages of the institutions of the Union, as indicated by the competent authority. For the purposes of this Regulation, the mandate shall empower the authorised representative to carry out the following tasks:

(a) verify that the EU declaration of conformity referred to in Article 47 and the technical documentation referred to in Article 11 have been drawn up and that an appropriate conformity assessment procedure has been carried out by the provider;

(b) keep at the disposal of the competent authorities and national authorities or bodies referred to in Article 74(10), for a period of 10 years after the high-risk AI system has been placed on the market or put into service, the contact details of the provider that appointed the authorised representative, a copy of the EU declaration of conformity referred to in Article 47, the technical documentation and, if applicable, the certificate issued by the notified body;

(c) provide a competent authority, upon a reasoned request, with all the information and documentation, including that referred to in point (b) of this subparagraph, necessary to demonstrate the conformity of a high-risk AI system with the requirements set out in Section 2, including access to the logs, as referred to in Article 12(1), automatically generated by the high-risk AI system, to the extent such logs are under the control of the provider;

(d) cooperate with competent authorities, upon a reasoned request, in any action the latter take in relation to the high-risk AI system, in particular to reduce and mitigate the risks posed by the high-risk AI system;

(e) where applicable, comply with the registration obligations referred to in Article 49(1), or, if the registration is carried out by the provider itself, ensure that the information referred to in point 3 of Section A of Annex VIII is correct.

The mandate shall empower the authorised representative to be addressed, in addition to or instead of the provider, by the competent authorities, on all issues related to ensuring compliance with this Regulation.

4. The authorised representative shall terminate the mandate if it considers or has reason to consider the provider to be acting contrary to its obligations pursuant to this Regulation. In such a case, it shall immediately inform the relevant market surveillance authority, as well as, where applicable, the relevant notified body, about the termination of the mandate and the reasons therefor.

What this article means in practice

Written by Engage Compliance. The text above is the article itself, reproduced from its official source and unchanged. Everything in this section is ours, and last read against the current text on 2026-09-07.

If you are established outside the EU and you want to make a high-risk AI system available on the Union market, Article 22 makes you appoint an authorised representative in the Union by written mandate before you do it, not after. The mandate is not a formality: it has to empower five specific tasks, and one of them runs for ten years after the system reaches the market.

Who it binds

  • Providers of high-risk AI systems established in third countries, before making the system available on the Union market (Article 22(1)). The trigger is the act of making available, so the appointment is a precondition of launch rather than a response to enforcement.
  • It does not bind providers established in the Union. The obligation is written for third-country providers only.
  • It says nothing about your size, your revenue or how many users you have. Unlike the general-purpose AI model rules, Article 22 carries no threshold at all: one high-risk system on the Union market is enough.
  • It binds the provider, not the deployer. A company using someone else's high-risk system in the EU has obligations under Article 26, which is a different article and a different role.

What it makes somebody do

  • You, the provider. Appoint the authorised representative by written mandate, before making the system available (Article 22(1)).
  • You, the provider. Enable the representative to actually perform what the mandate specifies (Article 22(2)). This is a duty on you, and it is where a thin appointment fails.
  • The representative. Verify that the EU declaration of conformity under Article 47 and the technical documentation under Article 11 have been drawn up, and that a conformity assessment has been carried out (Article 22(3)(a)).
  • The representative. Keep your contact details, the declaration of conformity, the technical documentation and any notified body certificate at the disposal of authorities for ten years after the system is placed on the market or put into service (Article 22(3)(b)).
  • The representative. On a reasoned request, give a competent authority everything needed to demonstrate conformity, including access to the logs generated under Article 12(1) where those logs are under your control (Article 22(3)(c)).
  • The representative. Cooperate with competent authorities on any action about the system, in particular to reduce and mitigate its risks (Article 22(3)(d)).
  • The representative. Comply with the Article 49(1) registration obligations, or where you register yourself, make sure the Annex VIII Section A point 3 information is correct (Article 22(3)(e)).
  • The representative. Terminate the mandate, and immediately tell the market surveillance authority and any notified body why, if it considers or has reason to consider that you are acting contrary to the Regulation (Article 22(4)).

What it does not say

  • It does not make the representative responsible for your compliance. The tasks in Article 22(3) are verification, custody, disclosure and cooperation. Building a conforming system stays yours.
  • It does not let you write whatever mandate you like. Article 22(3) says the mandate shall empower the representative to carry out those five tasks, so a mandate that omits one is defective rather than merely narrow.
  • The ten-year custody in Article 22(3)(b) is not ten years from appointment. It runs from the date the system was placed on the market or put into service, which usually precedes your appointment and which only you can tell the representative.
  • It is not a mailbox. Article 22(3) closes by empowering the representative to be addressed, in addition to or instead of you, by competent authorities on all issues related to compliance.
  • Article 22(4) is not boilerplate. The representative is required to walk away and report it, which means the appointment carries a genuine judgment the representative has to be resourced to make.

How it sits beside the other mandates

  • Article 22 and Article 54 are two different appointments. Article 22 is for high-risk systems, Article 54 for general-purpose AI models, and a company shipping a model inside its own high-risk system can be caught by both.
  • A company in scope of Article 22 is very often in scope of GDPR Article 27 as well, because a third-country provider placing an AI system on the Union market is usually also processing personal data of people in the EU. They are separate appointments with separate documents.
  • The ten-year retention outlives most commercial agreements. Whoever holds those documents has to still be there in year nine, which is a question worth asking of any provider before signing.

Source text: EUR-Lex, Official Journal HTML (CELEX 32024R1689). The parser was validated against the anchor articles verified in REP-08.